Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Standard BioTools Inc.’s mass cytometry systems shape immunotherapy studies worldwide, even a single line in the 10-K can move markets. Investors often ask, “Where can I review Standard BioTools quarterly earnings report 10-Q filing?” or “How do I track Standard BioTools insider trading Form 4 transactions?” Those answers live inside dense SEC documents—finding them can drain hours.
Stock Titan turns that complexity into clarity. Our AI delivers Standard BioTools SEC filings explained simply, spotlighting revenue from proteomics instruments, R&D cash burn, and obligations tied to leased manufacturing sites. You’ll see each Standard BioTools annual report 10-K simplified and Standard BioTools 8-K material events explained within minutes of hitting EDGAR. Real-time alerts surface Standard BioTools Form 4 insider transactions real-time, ensuring you never miss meaningful Standard BioTools executive stock transactions Form 4. Need faster context? Every Standard BioTools earnings report filing analysis pairs key metrics with peer benchmarks for immediate comparison.
Whether you’re building a valuation model or evaluating management incentives, critical disclosures are one click away:
- Track Standard BioTools proxy statement executive compensation to understand leadership alignment
- Compare margins and backlog across each Standard BioTools quarterly earnings report 10-Q filing
- Receive alerts on emerging risks via Standard BioTools 8-K material events explained
Understanding Standard BioTools SEC documents with AI means spending less time scrolling and more time deciding. Every filing, every footnote—decoded and delivered in real time.
Standard BioTools (NASDAQ:LAB) submitted a routine Form 4 disclosing director Troy Cox received 94,592 restricted stock units (RSUs) that vest in full by June 20 2026 and a stock option for 125,660 shares at an exercise price of $1.05, vesting in 12 equal monthly installments beginning July 20 2025.
Following these grants, Cox’s beneficial ownership stands at 256,412 common shares. No shares were sold, and the filing contains no additional transactions or financial disclosures.
Standard BioTools (NASDAQ:LAB) filed a Form 4 disclosing equity awards to director Kathy L. Hibbs executed on 20 Jun 2025.
The filing reports the grant of 94,592 restricted stock units (RSUs) that vest in full on 20 Jun 2026 or one day before the next annual shareholders’ meeting, contingent on continued service. Following the award, Hibbs’ direct ownership increased to 137,720 common shares.
In addition, Hibbs received a stock option for 125,660 shares exercisable at $1.05 per share. The option vests in twelve equal monthly instalments starting 20 Jul 2025 and expires 20 Jun 2035.
No shares were sold; all reported transactions were acquisitions recorded under direct ownership. The activity appears to reflect routine director compensation rather than open-market buying.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
What is the primary focus of Standard BioTools Inc.?
What technologies does Standard BioTools utilize?
How does Standard BioTools serve the research community?
What are the main business segments of Standard BioTools?
How does the company differentiate itself from competitors?
What kind of research applications benefit from Standard BioTools' technologies?
Who are the key customers of Standard BioTools?
How does Standard BioTools ensure quality and repeatability in its platforms?
